Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 800 entries
Sorted by: Best Match Show Resources per page
Lessons Learned from the NASA MOO Howard University Program for Underrepresented Minorities in Earth & Space Sciences

STEM and underrepresented

Misra P, Sakai R.
GSID: wFPDgCbm7KMJ
R Sakai, P Misra, WM Farrell… - AGU Fall Meeting …, 2018 - ui.adsabs.harvard.edu

This early opportunities research project is funded under the NASA Minority University Research and Education Other Opportunities (MOO) Program initiative and is a partnership between Howard University, University of Maryland Baltimore County (UMBC) and NASA Goddard Space Flight Center...

Cite
Sakai, R., Misra, P., Farrell, W. M., Meeson, B. W., Hoban, S., & Demoz, B. (2018, December). Lessons Learned from the NASA MOO Howard University Program for Underrepresented Minorities in Earth & Space Sciences. In AGU Fall Meeting Abstracts (Vol. 2018, pp. ED41A-07).
Sakai, R., et al. "Lessons Learned from the NASA MOO Howard University Program for Underrepresented Minorities in Earth & Space Sciences." AGU Fall Meeting Abstracts. Vol. 2018. 2018.
Copy Download .nbib Format: MLA
Effects of irbesartan on serum uric acid levels in patients with hypertension and diabetes.

Clinical pharmacology : advances and applications

Nakamura M, Sasai N, Hisatome I, Ichida K.
PMID: 24833923
Clin Pharmacol. 2014 May 03;6:79-86. doi: 10.2147/CPAA.S61462. eCollection 2014.

BACKGROUND: Hyperuricemia has been proposed to be a risk factor for cardiovascular disease and chronic kidney disease. Since diabetes is often complicated by hypertension and hyperuricemia, efficient therapeutic strategy against these two complications is very important in diabetic treatment....

Cite
Nakamura M, Sasai N, Hisatome I, et al. Effects of irbesartan on serum uric acid levels in patients with hypertension and diabetes. Clin Pharmacol. 2014;6:79-86doi: 10.2147/CPAA.S61462.
Nakamura, M., Sasai, N., Hisatome, I., & Ichida, K. (2014). Effects of irbesartan on serum uric acid levels in patients with hypertension and diabetes. Clinical pharmacology : advances and applications, 679-86. https://doi.org/10.2147/CPAA.S61462
Nakamura, Makiko, et al. "Effects of irbesartan on serum uric acid levels in patients with hypertension and diabetes." Clinical pharmacology : advances and applications vol. 6 (2014): 79-86. doi: https://doi.org/10.2147/CPAA.S61462
Nakamura M, Sasai N, Hisatome I, Ichida K. Effects of irbesartan on serum uric acid levels in patients with hypertension and diabetes. Clin Pharmacol. 2014 May 03;6:79-86. doi: 10.2147/CPAA.S61462. eCollection 2014. PMID: 24833923; PMCID: PMC4014383.
Copy Download .nbib Format: NLM
MRI-based cerebellar volume measurements correlate with the International Cooperative Ataxia Rating Scale score in patients with spinocerebellar degeneration or multiple system atrophy.

Cerebellum & ataxias

Hara D, Maki F, Tanaka S, Sasaki R, Hasegawa Y.
PMID: 27536377
Cerebellum Ataxias. 2016 Aug 17;3:14. doi: 10.1186/s40673-016-0052-4. eCollection 2016.

BACKGROUND: Progression of clinical symptoms and cerebellar atrophy may vary among subtypes of spinocerebellar degeneration and multiple system atrophy. The aim of this cross-sectional study was to demonstrate the relationship between the International Cooperative Ataxia Rating Scale (ICARS) score...

Cite
Hara D, Maki F, Tanaka S, et al. MRI-based cerebellar volume measurements correlate with the International Cooperative Ataxia Rating Scale score in patients with spinocerebellar degeneration or multiple system atrophy. Cerebellum Ataxias. 2016;3:14doi: 10.1186/s40673-016-0052-4.
Hara, D., Maki, F., Tanaka, S., Sasaki, R., & Hasegawa, Y. (2016). MRI-based cerebellar volume measurements correlate with the International Cooperative Ataxia Rating Scale score in patients with spinocerebellar degeneration or multiple system atrophy. Cerebellum & ataxias, 314. https://doi.org/10.1186/s40673-016-0052-4
Hara, Daisuke, et al. "MRI-based cerebellar volume measurements correlate with the International Cooperative Ataxia Rating Scale score in patients with spinocerebellar degeneration or multiple system atrophy." Cerebellum & ataxias vol. 3 (2016): 14. doi: https://doi.org/10.1186/s40673-016-0052-4
Hara D, Maki F, Tanaka S, Sasaki R, Hasegawa Y. MRI-based cerebellar volume measurements correlate with the International Cooperative Ataxia Rating Scale score in patients with spinocerebellar degeneration or multiple system atrophy. Cerebellum Ataxias. 2016 Aug 17;3:14. doi: 10.1186/s40673-016-0052-4. eCollection 2016. PMID: 27536377; PMCID: PMC4987966.
Copy Download .nbib Format: NLM
HBV Core Protein Enhances Cytokine Production.

Diseases (Basel, Switzerland)

Kanda T, Wu S, Sasaki R, Nakamura M, Haga Y, Jiang X, Nakamoto S, Yokosuka O.
PMID: 28943621
Diseases. 2015 Sep 17;3(3):213-220. doi: 10.3390/diseases3030213.

Hepatitis B virus (HBV) infection, a cause of hepatocellular carcinoma (HCC), remains a serious global health concern. HCC development and human hepatocarcinogenesis are associated with hepatic inflammation caused by host interferons and cytokines. This article focused on the association...

Cite
Kanda T, Wu S, Sasaki R, et al. HBV Core Protein Enhances Cytokine Production. Diseases. 2015;3(3):213-220doi: 10.3390/diseases3030213.
Kanda, T., Wu, S., Sasaki, R., Nakamura, M., Haga, Y., Jiang, X., Nakamoto, S., & Yokosuka, O. (2015). HBV Core Protein Enhances Cytokine Production. Diseases (Basel, Switzerland), 3(3), 213-220. https://doi.org/10.3390/diseases3030213
Kanda, Tatsuo, et al. "HBV Core Protein Enhances Cytokine Production." Diseases (Basel, Switzerland) vol. 3,3 (2015): 213-220. doi: https://doi.org/10.3390/diseases3030213
Kanda T, Wu S, Sasaki R, Nakamura M, Haga Y, Jiang X, Nakamoto S, Yokosuka O. HBV Core Protein Enhances Cytokine Production. Diseases. 2015 Sep 17;3(3):213-220. doi: 10.3390/diseases3030213. PMID: 28943621; PMCID: PMC5548245.
Copy Download .nbib Format: NLM
Focal partial salvage low-dose-rate brachytherapy for local recurrent prostate cancer after permanent prostate brachytherapy with a review of the literature.

Journal of contemporary brachytherapy

Kunogi H, Wakumoto Y, Yamaguchi N, Horie S, Sasai K.
PMID: 27504124
J Contemp Brachytherapy. 2016 Jun;8(3):165-72. doi: 10.5114/jcb.2016.60452. Epub 2016 Jun 13.

PURPOSE: To investigate the treatment results for focal partial salvage re-implantation against local recurrence after permanent prostate brachytherapy.MATERIAL AND METHODS: Between January 2010 and September 2015, 12 patients were treated with focal partial salvage re-implantation for local recurrence after...

Cite
Kunogi H, Wakumoto Y, Yamaguchi N, et al. Focal partial salvage low-dose-rate brachytherapy for local recurrent prostate cancer after permanent prostate brachytherapy with a review of the literature. J Contemp Brachytherapy. 2016;8(3):165-72doi: 10.5114/jcb.2016.60452.
Kunogi, H., Wakumoto, Y., Yamaguchi, N., Horie, S., & Sasai, K. (2016). Focal partial salvage low-dose-rate brachytherapy for local recurrent prostate cancer after permanent prostate brachytherapy with a review of the literature. Journal of contemporary brachytherapy, 8(3), 165-72. https://doi.org/10.5114/jcb.2016.60452
Kunogi, Hiroaki, et al. "Focal partial salvage low-dose-rate brachytherapy for local recurrent prostate cancer after permanent prostate brachytherapy with a review of the literature." Journal of contemporary brachytherapy vol. 8,3 (2016): 165-72. doi: https://doi.org/10.5114/jcb.2016.60452
Kunogi H, Wakumoto Y, Yamaguchi N, Horie S, Sasai K. Focal partial salvage low-dose-rate brachytherapy for local recurrent prostate cancer after permanent prostate brachytherapy with a review of the literature. J Contemp Brachytherapy. 2016 Jun;8(3):165-72. doi: 10.5114/jcb.2016.60452. Epub 2016 Jun 13. PMID: 27504124; PMCID: PMC4965495.
Copy Download .nbib Format: NLM
Dielectric Mismatch Mediates Carrier Mobility in Organic-Intercalated Layered TiS2.

Nano letters

Wan C, Kodama Y, Kondo M, Sasai R, Qian X, Gu X, Koga K, Yabuki K, Yang R, Koumoto K.
PMID: 26308495
Nano Lett. 2015 Oct 14;15(10):6302-8. doi: 10.1021/acs.nanolett.5b01013. Epub 2015 Sep 01.

The dielectric constant is a key parameter that determines both optical and electronic properties of materials. It is desirable to tune electronic properties though dielectric engineering approach. Here, we present a systematic approach to tune carrier mobilities of hybrid...

Cite
Wan C, Kodama Y, Kondo M, et al. Dielectric Mismatch Mediates Carrier Mobility in Organic-Intercalated Layered TiS2. Nano Lett. 2015;15(10):6302-8doi: 10.1021/acs.nanolett.5b01013.
Wan, C., Kodama, Y., Kondo, M., Sasai, R., Qian, X., Gu, X., Koga, K., Yabuki, K., Yang, R., & Koumoto, K. (2015). Dielectric Mismatch Mediates Carrier Mobility in Organic-Intercalated Layered TiS2. Nano letters, 15(10), 6302-8. https://doi.org/10.1021/acs.nanolett.5b01013
Wan, Chunlei, et al. "Dielectric Mismatch Mediates Carrier Mobility in Organic-Intercalated Layered TiS2." Nano letters vol. 15,10 (2015): 6302-8. doi: https://doi.org/10.1021/acs.nanolett.5b01013
Wan C, Kodama Y, Kondo M, Sasai R, Qian X, Gu X, Koga K, Yabuki K, Yang R, Koumoto K. Dielectric Mismatch Mediates Carrier Mobility in Organic-Intercalated Layered TiS2. Nano Lett. 2015 Oct 14;15(10):6302-8. doi: 10.1021/acs.nanolett.5b01013. Epub 2015 Sep 01. PMID: 26308495.
Copy Download .nbib Format: NLM
Correction for Devhare et al., "Exosome-Mediated Intercellular Communication between Hepatitis C Virus-Infected Hepatocytes and Hepatic Stellate Cells".

Journal of virology

Devhare PB, Sasaki R, Shrivastava S, Di Bisceglie AM, Ray R, Ray RB.
PMID: 28455354
J Virol. 2017 Apr 28;91(10). doi: 10.1128/JVI.00349-17. Print 2017 May 15.

No abstract available.

Cite
Devhare PB, Sasaki R, Shrivastava S, et al. Correction for Devhare et al., "Exosome-Mediated Intercellular Communication between Hepatitis C Virus-Infected Hepatocytes and Hepatic Stellate Cells". J Virol. 2017;91(10)doi: 10.1128/JVI.00349-17.
Devhare, P. B., Sasaki, R., Shrivastava, S., Di Bisceglie, A. M., Ray, R., & Ray, R. B. (2017). Correction for Devhare et al., "Exosome-Mediated Intercellular Communication between Hepatitis C Virus-Infected Hepatocytes and Hepatic Stellate Cells". Journal of virology, 91(10), . https://doi.org/10.1128/JVI.00349-17
Devhare, Pradip B, et al. "Correction for Devhare et al., "Exosome-Mediated Intercellular Communication between Hepatitis C Virus-Infected Hepatocytes and Hepatic Stellate Cells"." Journal of virology vol. 91,10 (2017). doi: https://doi.org/10.1128/JVI.00349-17
Devhare PB, Sasaki R, Shrivastava S, Di Bisceglie AM, Ray R, Ray RB. Correction for Devhare et al., "Exosome-Mediated Intercellular Communication between Hepatitis C Virus-Infected Hepatocytes and Hepatic Stellate Cells". J Virol. 2017 Apr 28;91(10). doi: 10.1128/JVI.00349-17. Print 2017 May 15. PMID: 28455354; PMCID: PMC5411579.
Copy Download .nbib Format: NLM
Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin.

Biology

Kanda T, Nakamura M, Yasui S, Haga Y, Tawada A, Suzuki E, Ooka Y, Takahashi K, Sasaki R, Wu S, Nakamoto S, Arai M, Imazeki F, Yokosuka O.
PMID: 28486403
Biology (Basel). 2017 May 09;6(2). doi: 10.3390/biology6020030.

The aim of this study was to characterize the treatment response and tolerability of sofosbuvir plus ribavirin therapies in Japanese patients infected with hepatitis C virus (HCV) genotype (GT)-2. This retrospective study analyzed 114 Japanese HCV GT-2 patients treated...

Cite
Kanda T, Nakamura M, Yasui S, et al. Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin. Biology (Basel). 2017;6(2)doi: 10.3390/biology6020030.
Kanda, T., Nakamura, M., Yasui, S., Haga, Y., Tawada, A., Suzuki, E., Ooka, Y., Takahashi, K., Sasaki, R., Wu, S., Nakamoto, S., Arai, M., Imazeki, F., & Yokosuka, O. (2017). Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin. Biology, 6(2), . https://doi.org/10.3390/biology6020030
Kanda, Tatsuo, et al. "Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin." Biology vol. 6,2 (2017). doi: https://doi.org/10.3390/biology6020030
Kanda T, Nakamura M, Yasui S, Haga Y, Tawada A, Suzuki E, Ooka Y, Takahashi K, Sasaki R, Wu S, Nakamoto S, Arai M, Imazeki F, Yokosuka O. Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin. Biology (Basel). 2017 May 09;6(2). doi: 10.3390/biology6020030. PMID: 28486403; PMCID: PMC5485477.
Copy Download .nbib Format: NLM
Frequency of nonsteroidal anti-inflammatory drug-associated ulcers.

Clinical journal of gastroenterology

Hiraishi H, Oki R, Tsuchida K, Yoshitake N, Tominaga K, Kusano K, Hashimoto T, Maeda M, Sasai T, Shimada T.
PMID: 26182316
Clin J Gastroenterol. 2012 Jun;5(3):171-6. doi: 10.1007/s12328-012-0300-y. Epub 2012 Apr 24.

Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for treatment of orthopedic diseases, inflammatory diseases, etc., and low-dose aspirin is a common antiplatelet therapy given mainly for secondary prevention of atherothrombosis (e.g., myocardial infarction and cerebral infarction). As to the...

Cite
Hiraishi H, Oki R, Tsuchida K, et al. Frequency of nonsteroidal anti-inflammatory drug-associated ulcers. Clin J Gastroenterol. 2012;5(3):171-6doi: 10.1007/s12328-012-0300-y.
Hiraishi, H., Oki, R., Tsuchida, K., Yoshitake, N., Tominaga, K., Kusano, K., Hashimoto, T., Maeda, M., Sasai, T., & Shimada, T. (2012). Frequency of nonsteroidal anti-inflammatory drug-associated ulcers. Clinical journal of gastroenterology, 5(3), 171-6. https://doi.org/10.1007/s12328-012-0300-y
Hiraishi, Hideyuki, et al. "Frequency of nonsteroidal anti-inflammatory drug-associated ulcers." Clinical journal of gastroenterology vol. 5,3 (2012): 171-6. doi: https://doi.org/10.1007/s12328-012-0300-y
Hiraishi H, Oki R, Tsuchida K, Yoshitake N, Tominaga K, Kusano K, Hashimoto T, Maeda M, Sasai T, Shimada T. Frequency of nonsteroidal anti-inflammatory drug-associated ulcers. Clin J Gastroenterol. 2012 Jun;5(3):171-6. doi: 10.1007/s12328-012-0300-y. Epub 2012 Apr 24. PMID: 26182316.
Copy Download .nbib Format: NLM
Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis.

Oncotarget

Kanda T, Yasui S, Nakamura M, Nakamoto S, Takahashi K, Wu S, Sasaki R, Haga Y, Ogasawara S, Saito T, Kobayashi K, Kiyono S, Ooka Y, Suzuki E, Chiba T, Maruyama H, Imazeki F, Moriyama M, Kato N.
PMID: 29545925
Oncotarget. 2018 Feb 03;9(14):11631-11637. doi: 10.18632/oncotarget.24391. eCollection 2018 Feb 20.

BACKGROUND: Interferon-free treatment can achieve higher sustained virological response (SVR) rates, even in patients in whom hepatitis C virus (HCV) could not be eradicated in the interferon treatment era. Immune restoration in the liver is occasionally associated with HCV...

Cite
Kanda T, Yasui S, Nakamura M, et al. Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis. Oncotarget. 2018;9(14):11631-11637doi: 10.18632/oncotarget.24391.
Kanda, T., Yasui, S., Nakamura, M., Nakamoto, S., Takahashi, K., Wu, S., Sasaki, R., Haga, Y., Ogasawara, S., Saito, T., Kobayashi, K., Kiyono, S., Ooka, Y., Suzuki, E., Chiba, T., Maruyama, H., Imazeki, F., Moriyama, M., & Kato, N. (2018). Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis. Oncotarget, 9(14), 11631-11637. https://doi.org/10.18632/oncotarget.24391
Kanda, Tatsuo, et al. "Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis." Oncotarget vol. 9,14 (2018): 11631-11637. doi: https://doi.org/10.18632/oncotarget.24391
Kanda T, Yasui S, Nakamura M, Nakamoto S, Takahashi K, Wu S, Sasaki R, Haga Y, Ogasawara S, Saito T, Kobayashi K, Kiyono S, Ooka Y, Suzuki E, Chiba T, Maruyama H, Imazeki F, Moriyama M, Kato N. Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis. Oncotarget. 2018 Feb 03;9(14):11631-11637. doi: 10.18632/oncotarget.24391. eCollection 2018 Feb 20. PMID: 29545925; PMCID: PMC5837765.
Copy Download .nbib Format: NLM
Successful Management of Graft Reinfection of HCV Genotype 2 in Living Donor Liver Transplantation from a Hepatitis B Core Antibody-Positive Donor with Sofosbuvir and Ribavirin.

Case reports in gastroenterology

Sasaki R, Kanda T, Ohtsuka M, Yasui S, Haga Y, Nakamura M, Yokoyama M, Wu S, Nakamoto S, Arai M, Maruyama H, Miyazaki M, Yokosuka O.
PMID: 27721720
Case Rep Gastroenterol. 2016 Jul 20;10(2):366-372. doi: 10.1159/000447423. eCollection 2016.

Direct-acting antivirals (DAAs) are relatively safe and highly effective for the eradication of hepatitis C virus (HCV) in liver transplant recipients. In this case study, we present a female with a graft reinfected with HCV genotype 2 who was...

Cite
Sasaki R, Kanda T, Ohtsuka M, et al. Successful Management of Graft Reinfection of HCV Genotype 2 in Living Donor Liver Transplantation from a Hepatitis B Core Antibody-Positive Donor with Sofosbuvir and Ribavirin. Case Rep Gastroenterol. 2016;10(2):366-372doi: 10.1159/000447423.
Sasaki, R., Kanda, T., Ohtsuka, M., Yasui, S., Haga, Y., Nakamura, M., Yokoyama, M., Wu, S., Nakamoto, S., Arai, M., Maruyama, H., Miyazaki, M., & Yokosuka, O. (2016). Successful Management of Graft Reinfection of HCV Genotype 2 in Living Donor Liver Transplantation from a Hepatitis B Core Antibody-Positive Donor with Sofosbuvir and Ribavirin. Case reports in gastroenterology, 10(2), 366-372. https://doi.org/10.1159/000447423
Sasaki, Reina, et al. "Successful Management of Graft Reinfection of HCV Genotype 2 in Living Donor Liver Transplantation from a Hepatitis B Core Antibody-Positive Donor with Sofosbuvir and Ribavirin." Case reports in gastroenterology vol. 10,2 (2016): 366-372. doi: https://doi.org/10.1159/000447423
Sasaki R, Kanda T, Ohtsuka M, Yasui S, Haga Y, Nakamura M, Yokoyama M, Wu S, Nakamoto S, Arai M, Maruyama H, Miyazaki M, Yokosuka O. Successful Management of Graft Reinfection of HCV Genotype 2 in Living Donor Liver Transplantation from a Hepatitis B Core Antibody-Positive Donor with Sofosbuvir and Ribavirin. Case Rep Gastroenterol. 2016 Jul 20;10(2):366-372. doi: 10.1159/000447423. eCollection 2016. PMID: 27721720; PMCID: PMC5043295.
Copy Download .nbib Format: NLM
Ingestibility and Formulation Quality of Lansoprazole Orally Disintegrating Tablets.

Journal of pharmaceutics

Chono S, Matsui M, Nakamura K, Kasai R.
PMID: 28044122
J Pharm (Cairo). 2016;2016:6131608. doi: 10.1155/2016/6131608. Epub 2016 Dec 01.

No abstract available.

Cite
Chono S, Matsui M, Nakamura K, et al. Ingestibility and Formulation Quality of Lansoprazole Orally Disintegrating Tablets. J Pharm (Cairo). 2016;2016:6131608doi: 10.1155/2016/6131608.
Chono, S., Matsui, M., Nakamura, K., & Kasai, R. (2016). Ingestibility and Formulation Quality of Lansoprazole Orally Disintegrating Tablets. Journal of pharmaceutics, 20166131608. https://doi.org/10.1155/2016/6131608
Chono, Sumio, et al. "Ingestibility and Formulation Quality of Lansoprazole Orally Disintegrating Tablets." Journal of pharmaceutics vol. 2016 (2016): 6131608. doi: https://doi.org/10.1155/2016/6131608
Chono S, Matsui M, Nakamura K, Kasai R. Ingestibility and Formulation Quality of Lansoprazole Orally Disintegrating Tablets. J Pharm (Cairo). 2016;2016:6131608. doi: 10.1155/2016/6131608. Epub 2016 Dec 01. PMID: 28044122; PMCID: PMC5156814.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 800 entries